Drug intelligence / Profile preview

methandienone

Development stage
Discontinued
Lead developer
Novartis
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

**Methandienone** is a synthetic androgen and anabolic steroid (AAS), originally developed by CIBA in 1955, and marketed under the brand name Dianabol. It is primarily used non-medically for physique and performance enhancement, especially by bodybuilders and athletes, due to its potent anabolic properties. Methandienone functions mainly as a strong agonist of the androgen receptor, promoting enhanced protein synthesis, nitrogen retention, and glycogenolysis in muscle tissue. This leads to rapid increases in muscle mass and strength, as well as accelerated recovery. It also has moderate androgenic and estrogenic effects, including the development of male secondary sexual characteristics and estrogen-related side effects such as gynecomastia and fluid retention. Methandienone is orally active and its use may result in hepatotoxicity. Its medical use for androgen replacement therapy in conditions like hypogonadism has largely been discontinued, but it remains popular in some countries for non-medical use[1][2][3][5].

Brand names
DianabolD-Bol
Other names
metandienonemethandrostenolonedehydromethyltestosteronemétandiénonemetandienonu17α-methyl-δ^1^-testosterone17α-methylandrost-1,4-dien-17β-ol-3-one
02

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on methandienone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on methandienone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call